ILMN — Illumina, Inc.
Healthcare · ETF XLV · as of 2026-09-18
Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
Illumina, Inc.
NMS
Healthcare · Diagnostics & Research
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Price & today
$239.62
ATR(14) 10.35 (4.32%)
| Stock today | -2.27% |
| Sector ETF today | -0.25% |
| Residual (stock-specific) | -2.02% |
Sector correlation
| 20-day correlation with XLV | 0.42 |
| 60-day correlation with XLV | 0.25 |
| Status | normal |
Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.
Technicals
| 10 EMA | $224.01 |
| 20 EMA | $217.49 |
| 50 EMA | $204.06 |
| EMA stack | BULLISH |
| RSI(14) | 65.7 |
| 52-week high distance | +15.76% |
| 52-week low distance | +172.30% |
Signals
| Market F&G | 46.9 |
| Bull% | 12.2% |
| OVTLYR status | SELL (5d) |
| Sector rank | #514 |
| Next earnings | 2026-10-28 (AMC, 39d) |
MarketSmith metrics - our compute
RS Rating
95.7
ADR%
4.5
RMV (tight)
77.0
Ext (ATR>20EMA)
2.1
Rel Vol
1276.0%
U/D 50d
0.78
U/D 25d
0.67
Accum/Dist 25d
8 / 2
EPS YoY
+10.0%
LoD dist
31.0
Off 52w High
4.2%
Above 52w Low
172.3%
1W / 1M
+16.1 / +16.9
Avg $Vol 50d
547.9M
Mkt Cap (B)
36.3
Trend 8/8
YES
Leads Group
YES
Sector XLV
+1.8% 1W
Base len (VCP)
15wk (5/10)
Coil (base shape)
85TVPX
What do these abbreviations mean?
- RS Rating
- - IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
- ADR%
- - average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
- RMV (tight)
- - Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
- Ext (ATR>20EMA)
- - how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
- Rel Vol
- - latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
- U/D 50d / 25d
- - up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
- Accum/Dist 25d
- - heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
- LoD dist
- - close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
- Off/Above 52w
- - trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
- Trend 8/8
- - all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
- Base len (VCP)
- - weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.
Fundamentals & valuation - reference, not entry inputs
P/E (TTM)
44.7
Fwd P/E
39.4
PEG
2.7
Price/Book
10.0
Profit margin
18.3%
ROE
32.3%
Debt/Equity
89.0
Rev growth
+9.4%
Analyst target
$196 (-18%)
Analyst rating
HOLD
Institutional %
108.3%
Insider %
0.2%
Float %
96.4%
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.
Company data - context read, not entry inputs
Industry rank
1 / 147
Industry
Diagnostics & Research
Float
145.9M
Float turnover 20d
2.5%
Avg $Vol 20d / 50d
827.7M / 547.9M
Days to cover
4.2
Short % float
9.5%
Institutional %
108.3%
Weinstein stage
2
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.
Quarterly EPS - earnings acceleration
A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.
| Quarter | EPS ($) | %Chg YoY | Sales ($M) | %Chg |
|---|---|---|---|---|
| Nov-24 | 1.14 | +245% | 1,080.0 | -3% |
| Feb-25 | 0.86 | +514% | 1,104.0 | -2% |
| May-25 | 0.97 | +978% | 1,041.0 | -3% |
| Jul-25 | 1.19 | +231% | 1,059.0 | -5% |
| Oct-25 | 1.34 | +18% | 1,084.0 | +0% |
| Feb-26 | 1.35 | +57% | 1,159.0 | +5% |
| Apr-26 | 1.15 | +19% | 1,091.0 | +5% |
| Jul-26 | 1.31 | +10% | 1,159.0 | +9% |
† = SEC carries this same fiscal quarter under a second period-end with a materially different figure (hover for it) - a restatement, merger recast or successor-period split; %Chg is blanked when the two are more than 15% apart. It fires only when the two period-ends DISAGREE, so it is a floor, not a guarantee that the rest of the column shares one basis · ‡ = the revenue concept changed from the previous quarter WITH A FIGURE (hover for both) - a blank row in between is skipped, as the eye does - a step at that row is a change of basis, not necessarily of business · EPS = Yahoo
eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).Recent news - our DB (Finnhub + OVTLYR)
- Sep 18 · Genomics Market Outlook 2026-2035 - Featuring Profiles of Illumina, Thermo Fisher Scientific, and Qiagen Yahoo
- Sep 18 · Pharmacogenomics Market Outlook 2026-2035 - Featuring Profiles of Thermo Fisher Scientific, Illumina, and Qiagen Yahoo
- Sep 18 · Illumina Reports Q2 2026 Results: Full Earnings Call Transcript Benzinga
- Sep 17 · Is Brookdale Senior Living (BKD) Outperforming Other Medical Stocks This Year? Yahoo
- Sep 16 · Three Stocks Are Joining the S&P 500. Will They Actually Improve VOO’s Returns? Yahoo
- Sep 16 · Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today Benzinga
- Sep 16 · LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday Benzinga
- Sep 16 · US Stock Market Today: S&P 500 Futures Edge Higher As Bond Yield Jitters Linger Yahoo